Fluctuation of systemic immunity in melanoma and implications for timing of therapy.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Frontiers in Bioscience

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2741/433PMID 22201928
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy for melanoma

  2011cited by this paper
• Dysregulation of Inflammatory Responses by Chronic Circadian Disruption

  2010cited by this paper
• Fluctuation of Peripheral Blood T, B, and NK Cells during a Menstrual Cycle of Normal Healthy Women

  2010cited by this paper
• Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy

  2010cited by this paper
• Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma

  2009cited by this paper
• The role of cell‐specific circadian clocks in metabolism and disease

  2009cited by this paper
• Increasing burden of melanoma in the United States.

  2009influential reference
• Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

  2009cited by this paper
• Cortisol and epinephrine control opposing circadian rhythms in T cell subsets.

  2009cited by this paper
• Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.

  2008cited by this paper
• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  2008cited by this paper
• Next generation of immunotherapy for melanoma.

  2008cited by this paper
• Stability of soluble adhesion molecules, selectins, and C-reactive protein at various temperatures: implications for epidemiological and large-scale clinical studies.

  2007cited by this paper
• Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy

  2007cited by this paper
• Melanoma immunology: past, present and future

  2007cited by this paper
• Diurnal, Seasonal, and Blood-Processing Patterns in Levels of Circulating Fibrinogen, Fibrin D-Dimer, C-Reactive Protein, Tissue Plasminogen Activator, and von Willebrand Factor in a 45-Year-Old Population

  2007cited by this paper
• Both Regulatory T Cells and Antitumor Effector T Cells Are Primed in the Same Draining Lymph Nodes during Tumor Progression1

  2005cited by this paper
• Comparison of differing C-reactive protein assay methods and their impact on cardiovascular risk assessment.

  2005cited by this paper
• Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy

  2004cited by this paper
• Timed Ablation of Regulatory CD4+ T Cells Can Prevent Murine AIDS Progression

  2004cited by this paper
• Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.

  2004cited by this paper
• Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting

  2004cited by this paper
• Computational approaches to cellular rhythms

  2002cited by this paper
• Marker rhythms of circadian system function: a study of patients with metastatic colorectal cancer and good performance status

  2002cited by this paper
• Rotating night shifts and risk of breast cancer in women participating in the nurses' health study.

  2001cited by this paper
• Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

  2001cited by this paper
• Circadian rhythm chaos: a new breast cancer marker.

  2001cited by this paper
• Increased Breast Cancer Risk among Women Who Work Predominantly at Night

  2001cited by this paper
• Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

  2000cited by this paper
• Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

  2000cited by this paper
• O(6)-benzylguanine enhances the in vitro immunotoxic activity of temozolomide on natural or antigen-dependent immunity.

  1999cited by this paper
• Tietz textbook of Clinical Chemistry

  1994cited by this paper
• Circadian cancer therapy.

  1994cited by this paper
• Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma.

  1990cited by this paper
• Circadian timing of cancer chemotherapy.

  1985cited by this paper
• Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells

  1984cited by this paper
• Chronobiology in hematology and immunology.

  1983cited by this paper
• Studies on the bioperiodicity of the immune response. I. Circadian rhythms of human T, B, and K cell traffic in the peripheral blood.

  1981cited by this paper
• Cyclical changes in susceptibility of a myeloma tumor (LPC-1) to immune destruction. III. Periodic production of a cell surface glycoprotein and changes in reactivity with cytotoxic T cells and anti-H-2d sera.

  1979cited by this paper
• Cyclical changes in susceptibility of a myeloma tumor (LPC-1) to immune destruction. I. Changes in reactivity with cytotoxic T lymphocytes and anti-H-2d sera.

  1979cited by this paper
• Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y.

  1977cited by this paper

• A Partial Tumor Irradiation Approach for Complex Bulky Disease.

  2024cites this paper
• The immune system contributes to the effectiveness of vaccine therapy in patients with metastatic melanoma

  2023cites this paper
• Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer

  2020cites this paper
• Shifting the Immune-Suppressive to Predominant Immune-Stimulatory Radiation Effects by SBRT-PArtial Tumor Irradiation Targeting HYpoxic Segment (SBRT-PATHY)

  2020cites this paper
• Resistance to chemoimmunotherapy in non-small-cell lung cancer

  2020cites this paper
• The future of radiation-induced abscopal response: beyond conventional radiotherapy approaches.

  2020cites this paper
• Circadian Rhythms and Personalized Melanoma Therapy

  2019cites this paper
• Immune Checkpoint Molecules and Cancer Immunotherapy

  2019cites this paper
• Time-synchronized immune-guided SBRT partial bulky tumor irradiation targeting hypoxic segment while sparing the peritumoral immune microenvironment

  2019cites this paper
• Effect of lymphocyte morphogenetic activity on organism reactivity and resistibility

  2018cites this paper
• Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

  2018cites this paper
• Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients

  2017cites this paper
• GPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease

  2017cites this paper
• Aquaporin-4 mediates communication between astrocyte and microglia: Implications of neuroinflammation in experimental Parkinson's disease.

  2016cites this paper
• Gene expression patterns in CD4+ peripheral blood cells in healthy subjects and stage IV melanoma patients

  2015cites this paper
• Nanoparticle-Based and Bioengineered Probes and Sensors to Detect Physiological and Pathological Biomarkers in Neural Cells

  2015cites this paper
• A role for mitogen-activated protein kinase phosphatase 1 (MKP1) in neural cell development and survival

  2015cites this paper
• The Immune System and Responses to Cancer: Coordinated Evolution

  2015cites this paper
• Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.

  2014cites this paper
• Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma

  2014cites this paper
• Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations

  2014cites this paper
• Personalized therapy for metastatic melanoma: could timing be everything?

  2012influential citation
• Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation

  2012cites this paper
• Towards Systems Based Immunotherapy of Cancer

  2012cites this paper
• The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses

  2012cites this paper
• The dynamic human immune response to cancer: it might just be rocket science.

  2011cites this paper